Showing results (211-220 of 234) with videos related to
Sort By:
Pageof 24
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 2, 2024
The Prostaglandin EP4 Antagonist Vorbipiprant Combined with PD-1 Blockade for Refractory Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib/IIa TrialFilippo Pietrantonio, Federica Morano, Monica Niger, et al.Biorxiv : the Preprint Server for Biology|February 17, 2023
Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapyYaniv Kazansky, Daniel Cameron, Helen S Mueller, et al.Oncotarget|October 6, 2016
Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition frameworkFabio Bozzi, Silvia Brich, Gian Paolo Dagrada, et al.Cancer Discovery|February 5, 2024
Overcoming Clinical Resistance to EZH2 Inhibition Using Rational Epigenetic Combination TherapyYaniv Kazansky, Daniel Cameron, Helen S Mueller, et al.Urologic Oncology|September 16, 2017
Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 studyAndrea Necchi, Salvatore Lo Vullo, Daniele Raggi, et al.Chemistry (Weinheim an Der Bergstrasse, Germany)|August 20, 2015
Activation of Hsp90 Enzymatic Activity and Conformational Dynamics through Rationally Designed Allosteric LigandsSara Sattin, Jiahui Tao, Gerolamo Vettoretti, et al.Journal of Experimental & Clinical Cancer Research : CR|March 2, 2021
Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulationValentina Zuco, Sandro Pasquali, Monica Tortoreto, et al.The Journal of Clinical Investigation|August 12, 2025
Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomasYaniv Kazansky, Helen S Mueller, Daniel Cameron, et al.The Lancet. Oncology|July 24, 2012
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trialAndrea Necchi, Luigi Mariani, Nadia Zaffaroni, et al.Biorxiv : the Preprint Server for Biology|May 20, 2024
Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomasYaniv Kazansky, Helen S Mueller, Daniel Cameron, et al.Pageof 24